Genetically modified microorganism for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid and method for producing such chemical

By increasing the expression amount of the organophosphate compound discharge carrier in microorganisms, the problem of low productivity of 3-hydroxyadipic acid and 3-oxoadipic acid in the prior art is solved, and the effect of efficient production of these compounds is achieved.

CN118922530APending Publication Date: 2024-11-08TORAY INDUSTRIES INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202380027530.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-23
Filing Date
2023-03-22
Publication Date
2024-11-08

Smart Images

  • Figure BDA0005042127000000051
    Figure BDA0005042127000000051
Patent Text Reader

Abstract

Disclosed are: a genetically modified microorganism capable of producing 3-hydroxyadipic acid and / or 3-oxoadipic acid with high productivity; and a method for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid using the genetically modified microorganism. The genetically modified microorganism has enhanced activity of an enzyme that catalyzes a reaction from succinyl-CoA and acetyl-CoA to 3-oxoadipyl-CoA and CoA in a microorganism having the ability to produce 3-hydroxyadipic acid and / or 3-oxoadipic acid, and a genetically modified microorganism in which the expression amount of an organic phosphate compound excreting carrier or a homolog thereof is increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a genetically modified microorganism that produces 3-hydroxyadipic acid and / or 3-oxoadipic acid at a high yield, and a method for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid using the genetically modified microorganism. Background Art

[0002] 3-Hydroxyadipic acid (IUPAC name: 3-hydroxyhexanedioic acid) is a dicarboxylic acid having 6 carbon atoms. It can be used as a raw material for forming polyester by polymerization with polyols or for forming polyamide by polymerization with polyamines. In addition, compounds formed by lactamization by adding ammonia to their ends can also be used as a raw material for polyamide.

[0003] 3-Oxoadipic acid (also known as β-ketoadipic acid, IUPAC name: 3-oxohexanedioic acid) is a dicarboxylic acid having 6 carbon atoms and a molecular weight of 160.12. 3-Oxoadipic acid can be used as a raw material for forming polyester by polymerization with polyols or for forming polyamide by polymerization with polyamines. In addition, 3-Oxoadipic acid can be used alone as a raw material for polyamide by adding ammonia to the end of the 3-oxoadipic acid to form lactam.

[0004] As documents related to the production of 3-hydroxyadipic acid or 3-oxoadipic acid using microorganisms, Patent Document 1 discloses a method for producing 3-hydroxyadipic acid using a Serratia microorganism having enhanced enzyme activity that catalyzes the reaction from succinyl-CoA and acetyl-CoA to 3-oxoadipic-CoA and CoA. In addition, Patent Document 2 reports that 3-oxoadipic acid (3-oxoadipic), an intermediate in the adipic acid biosynthesis pathway, can be produced during a method for producing adipic acid using a naturally non-natural microorganism using succinyl-CoA and acetyl-CoA as starting materials.

[0005] In addition, in the method of producing chemicals using microorganisms, an export carrier (transporter) that excretes the chemical to be produced from the cell is used (for example, Patent Document 3 and Non-Patent Documents 1 and 2). Patent Document 4 describes a method for producing 3-hydroxyadipic acid and / or α-hydrogenated adipate using a genetically modified microorganism in which the function of a dicarboxylic acid export carrier is defective or reduced. As the biosynthetic pathway of these substances, it is described that the productivity of these substances is improved by converting succinyl-CoA and acetyl-CoA to 3-oxoadipoyl-CoA and CoA through an enzyme reaction, and by defecting or reducing the function of the dicarboxylic acid export carrier.

[0006] Prior art literature

[0007] Patent Literature

[0008] Patent document 1: WO2017 / 209102

[0009] Patent document 2: WO2009 / 151728

[0010] Patent Document 3: Japanese Patent Application No. 2017-528126

[0011] Patent document 4: WO2021 / 187533

[0012] Non-patent literature

[0013] Non-patent literature 1: J. Ind. Microbiol Biotechnol. 2012Apr; 39(4): 641-7

[0014] Non-patent document 2: Pesticide Biochemistry and Physiology 140 (2017) 65-68 Summary of the invention

[0015] Problems to be solved by the invention

[0016] The present invention aims to create a genetically modified microorganism capable of producing 3-hydroxyadipic acid and / or 3-oxoadipic acid with high productivity, and a method for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid using the genetically modified microorganism.

[0017] Means for solving problems

[0018] In order to achieve the above-mentioned purpose, the present inventors conducted intensive studies and found that the productivity of 3-hydroxyadipic acid and / or 3-oxoadipic acid can be improved by increasing the expression level of an excretion vector of an organic phosphate compound, which is a substance completely unrelated to 3-hydroxyadipic acid and / or 3-oxoadipic acid, in a microorganism having the ability to produce 3-hydroxyadipic acid and / or 3-oxoadipic acid, thereby completing the present invention.

[0019] That is, the present invention provides the following (1) to (13).

[0020] (1) A genetically modified microorganism having enhanced activity of an enzyme that catalyzes the reaction from succinyl-CoA and acetyl-CoA to 3-oxoadipyl-CoA and CoA in a microorganism capable of producing 3-hydroxyadipate and / or 3-oxoadipate, and increased expression of an organophosphate compound excretion vector.

[0021] (2) The genetically modified microorganism according to (1), wherein the organophosphate compound excretion carrier is a phosphoserine excretion carrier and / or a glyphosate excretion carrier.

[0022] (3) The genetically modified microorganism according to (1) or (2), wherein the organophosphate compound excretion carrier is YhhS, MdtD, RhtB, MFS40 or a homolog thereof.

[0023] (4) The genetically modified microorganism according to any one of (1) to (3), wherein the expression level of the organophosphate compound excretion vector is increased by introducing a gene encoding a polypeptide of any one of the following (A) to (C),

[0024] (A) a polypeptide consisting of the amino acid sequence of SEQ ID NOs: 1, 3, 28 to 30, 46, 48 or 50;

[0025] (B) a polypeptide having a sequence identity of 60% or more to the amino acid sequence of SEQ ID NOs: 1, 3, 28 to 30, 46, 48 or 50, and having a function of increasing the productivity of 3-hydroxyadipic acid and / or 3-oxoadipic acid;

[0026] (C) A polypeptide consisting of an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added in the amino acid sequence of SEQ ID NOs: 1, 3, 28 to 30, 46, 48 or 50, and having a function of increasing the productivity of 3-hydroxyadipic acid and / or 3-oxoadipic acid.

[0027] (5) The genetically modified microorganism according to any one of (1) to (4), further comprising an enhanced activity of an enzyme that catalyzes the reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA and / or the reaction of producing 3-hydroxyadipic acid from 3-hydroxyadipyl-CoA.

[0028] (6) The genetically modified microorganism according to any one of (1) to (5), wherein the activity of an enzyme that catalyzes the reaction of producing 3-oxoadipate from 3-oxoadipyl-CoA is further enhanced.

[0029] (7) The genetically modified microorganism according to any one of (1) to (6), wherein the microorganism is a microorganism belonging to the genus Escherichia or Serratia.

[0030] (8) A method for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid, comprising the step of culturing the genetically modified microorganism according to any one of (1) to (7).

[0031] (9) A method for producing a genetically modified microorganism, comprising: a step of enhancing the activity of an enzyme that catalyzes the reaction from succinyl-CoA and acetyl-CoA to 3-oxoadipyl-CoA and CoA in a microorganism having the ability to produce 3-hydroxyadipic acid and / or 3-oxoadipic acid by genetic modification; and a step of increasing the expression level of YhhS or a homolog thereof in the microorganism.

[0032] (10) A method for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid, comprising the step of culturing a microorganism capable of producing 3-hydroxyadipic acid and / or 3-oxoadipic acid in which the expression level of an organophosphate compound excretion vector is increased.

[0033] (11) A method for producing adipic acid, comprising: a step A of producing 3-hydroxyadipic acid and / or 3-oxoadipic acid by the method described in (8) or (10); and a step B (i.e., a hydrogenation step) of reacting 3-hydroxyadipic acid and / or 3-oxoadipic acid with hydrogen in the presence of a hydrogenation catalyst.

[0034] (12) A method for producing a polyamide, comprising: a step of producing adipic acid by the method described in (11); and a step C of polycondensing adipic acid and a diamine.

[0035] (13) The method for producing a polyamide according to (11), wherein the diamine is a diamine containing 1,4-butanediamine, 1,5-pentanediamine, or hexamethylenediamine.

[0036] Effects of the Invention

[0037] The genetically modified microorganism of the present invention can produce 3-hydroxyadipic acid and / or 3-oxoadipic acid at a high productivity compared to the parent microorganism in which the expression amount of the organophosphate compound excretion vector is not increased. DETAILED DESCRIPTION

[0038] Hereinafter, in this specification, 3-hydroxyadipic acid is sometimes abbreviated as 3HA, and 3-oxoadipic acid is abbreviated as 3OA. In addition, a gene encoding YhhS is sometimes recorded as yhhS. In addition, a gene encoding MdtD is sometimes recorded as mdtD. In addition, a gene encoding RhtB is sometimes recorded as rhtB. In addition, a gene encoding EmrD is sometimes recorded as emrD. In addition, 3-oxoadipoyl-CoA is sometimes abbreviated as 3OA-CoA, 3-hydroxyadipoyl-CoA is abbreviated as 3HA-CoA, and coenzyme A is abbreviated as CoA. In addition, a nucleic acid encoding a functional polypeptide is sometimes recorded as a gene.

[0039] The following reaction scheme 1 shows an example of a reaction pathway for microorganisms to produce 3HA and / or 3OA. Here, reaction A represents the reaction of generating 3-oxoadipyl-CoA and CoA from acetyl-CoA and succinyl-CoA. Reaction B represents the reaction of reducing 3-oxoadipyl-CoA to generate 3-hydroxyadipyl-CoA. Reaction C represents the reaction of generating 3-hydroxyadipic acid from 3-hydroxyadipyl-CoA. Reaction D represents the reaction of generating 3-oxoadipate from 3-oxoadipyl-CoA. It is known that among these reaction pathways, microorganisms having the ability to produce 3HA and / or 3OA have at least an enzyme that catalyzes reaction A (see WO2019 / 107516).

[0040] [Chemical formula 1]

[0041]

[0042] Then, the technical feature of the genetically modified microorganism of the present invention is that the productivity of 3HA and / or 3OA in the microorganism capable of producing 3HA and / or 3OA is improved by enhancing the activity of the enzyme in the reaction (reaction A) of generating 3-oxoadipyl-CoA and CoA from acetyl-CoA and succinyl-CoA in the microorganism capable of producing 3HA and / or 3OA, and increasing the expression level of the organophosphate compound excretion vector. It should be noted that "genetic modification" refers to artificially changing genes.

[0043] The organic phosphoric acid compound refers to a compound having a structure in which an organic compound such as an alcohol, a carboxylic acid, or an amino acid is bonded to phosphoric acid. Specific examples thereof include: phosphoserine, which is an ester bond between serine, an amino acid having a hydroxyl group, and phosphoric acid; and glyphosate, which is a substitution of a phosphoric acid methyl group on the nitrogen atom of glycine.

[0044] An organophosphate compound excretion carrier is a membrane protein having the activity of excreting an organophosphate compound in a cell to the outside of the cell. In addition, increasing the expression level of an organophosphate compound excretion carrier means increasing the expression level of a protein having an organophosphate compound excretion function originally possessed by a microorganism, and / or causing a protein having an organophosphate compound excretion function not originally possessed by a microorganism to be expressed in the microorganism. Preferred specific examples of an organophosphate compound excretion carrier whose expression level is increased in the present invention include a phosphoserine excretion carrier and / or a glyphosate excretion carrier.

[0045] Specific examples of the phosphoserine excretion carrier include YhhS, MdtD, and RhtB proteins described in JP-A No. 2017-528126 as O-phosphoserine excretion carriers, and homologs of these proteins.

[0046] Specific examples of glyphosate excretion carriers include the YhhS protein and its homologs described in J. Ind. Microbiol Biotechnol. 2012 Apr; 39(4): 641-7; and the MFS40 protein and its homologs described in Pesticide Biochemistry and Physiology 140(2017) 65-68.

[0047] It should be noted that in the above-mentioned documents cited in the description of specific examples of phosphoserine excretion carriers and glyphosate excretion carriers, there is no record that the organophosphate compound excretion carrier exemplified by YhhS etc. has activity as a dicarboxylic acid excretion carrier. Therefore, as shown in the embodiments of the present specification, by increasing the expression level of the organophosphate compound excretion carrier, the production capacity of 3HA and / or 3OA, which are dicarboxylic acids having 6 carbon atoms, is improved, which means that the organophosphate compound excretion carrier has the function of an excretion carrier of 3HA and / or 3OA. For those skilled in the art, it is an unexpected discovery that the organophosphate compound excretion carrier also functions as an excretion carrier of 3HA and / or 3OA.

[0048] Hereinafter, YhhS, MdtD, RhtB, and MFS40, and homologs thereof, which are suitable as the organophosphate compound excretion vector for increasing the expression level in the present invention, will be described in detail.

[0049] YhhS is a protein presumed to be a major facilitator superfamily (MFS)-type transporter, and as a specific example, YhhS from Escherichia coli str.K-12substr.MG1655 (NCBI ProteinID: NP_417930, sequence number 1) can be cited, and as a yhhS gene encoding the YhhS protein, yhhS from Escherichia coli str.K-12substr.MG1655 strain (NCBI GeneID: 947982, sequence number 2) can be cited. In addition, if it is composed of an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added in the amino acid sequence of sequence number 1, and has a function of increasing the productivity of 3HA and / or 3OA by increasing its expression level, then the protein can be used as YhhS. Here, the range of "1 or more" is preferably within 10, more preferably within 5, further preferably within 4, and particularly preferably within 1 or 2. In addition, a protein consisting of an amino acid sequence having a sequence identity (defined below) of 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, further preferably 95% or more, further preferably 97% or more, further preferably 98% or more, further preferably 99% or more with respect to the amino acid sequence of SEQ ID NO: 1 and having a function of increasing the productivity of 3HA and / or 3OA by increasing the expression amount thereof can also be used as YhhS.

[0050] A homolog of YhhS is a protein presumed to have a high sequence identity with the amino acid sequence of YhhS and to have a function or structure similar to that of YhhS.

[0051] For example, by using the amino acid sequence of YhhS as a query sequence, performing a BLAST (Basic Local Alignment Search Tool) search on a public database such as NCBI (National Center for Biotechnology Information) or KEGG (Kyoto Encyclopedia of Genes and Genomes), and referring to the gene encoding the searched sequence, a homolog of YhhS can be easily obtained. Alternatively, it can also be obtained by performing PCR using oligonucleotides prepared based on the base sequence of a gene encoding YhhS or its homolog as primers and using genomic DNA of other organisms as a template.

[0052] A homolog of YhhS is a protein presumed to have a high sequence identity with the amino acid sequence of YhhS and a function or structure similar to that of YhhS. The following homologs can be used: relative to the amino acid sequence of YhhS from Escherichia coli str.K-12 substr.MG1655 (NCBI Protein ID: NP_417930, sequence number 1), the sequence identity is specifically 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, and particularly preferably 95% or more, and has a function of increasing the productivity of 3HA and / or 3OA by increasing their expression level. Specific examples of such YhhS homologs include: a YhhS homolog from Serratia grimesii NBRC13537 strain (sequence number 3), a YhhS homolog from Salmonella enterica ATCC9150 strain (NCBI Protein ID: AAV79243, sequence number 28), a YhhS homolog from Klebsiella pneumoniae MGH78578 strain (NCBI Protein ID: ABR79226, sequence number 29), and a YhhS homolog from Pectobacterium carotovorum PC1 strain (NCBI Protein ID: ACT11150, sequence number 30). Genes encoding these proteins include: a YhhS homolog from Serratia grimesii NBRC13537 strain (sequence number 4), a YhhS homolog from Salmonella enterica The yhhS homolog of ATCC9150 strain (NCBI GeneID: CP000026, REGION: 3539049..3540266, sequence number 31), the yhhS homolog from Klebsiella pneumoniae MGH78578 strain (NCBI GeneID: CP000647, REGION: 4195189..4196409, sequence number 32), and the yhhS homolog from Pectobacterium carotovorum PC1 strain (NCBI GeneID: CP001657, REGION: 113478..114677, sequence number 33).It should be noted that, in the present specification and claims, "sequence identity" refers to the ratio (percentage) of the same amino acid or base relative to the entire overlapping amino acid sequence (including the amino acid as the translation start point) or base sequence (including the start codon) in the optimal alignment (alignment) when a gap is introduced or not introduced in two amino acid sequences or base sequences, calculated according to formula (1). In formula (1), the sequence length of the shorter one is 100 amino acids or more than 300 bases, and it is not defined as sequence identity when it is less than 100 amino acids or 300 bases. Sequence identity can be easily studied, for example, using the default parameters in BLAST. In addition, sequence identity can also be studied using the same function carried by software such as Genetyx. According to formula (1), when the sequence identity between the amino acid sequences of sequence numbers 1, 28, 29, 30 and 3 is calculated using the function (% Identity Matrix) of Genetyx, it is 90.9, 84.4, 70.2 and 61.4% respectively.

[0053] Sequence identity (%) = number of identical sequences (intervals are not counted) / length of the shorter sequence (excluding the length of the intervals at both ends) × 100...Formula (1).

[0054] MdtD (also known as YegB) is a protein belonging to the major facilitator superfamily (MFS) of putative multidrugresistance proteins, and specific examples thereof include MdtD from Escherichia coli str. K-12 substr. MG1655 (NCBI Protein ID: NP_416581, sequence number 46), and genes encoding MdtD include mdtD from Escherichia coli str. K-12 substr. MG1655 (NCBI Gene ID: 946601, sequence number 47). In addition, if a protein is composed of an amino acid sequence in which one or more amino acids are substituted, deleted, inserted, and / or added in the amino acid sequence of sequence number 46, and has a function of increasing the productivity of 3HA and / or 3OA by increasing its expression level, the protein can be used as MdtD. Here, the range of "1 or more" is preferably within 10, more preferably within 5, further preferably within 4, and particularly preferably within 1 or 2. In addition, a protein consisting of an amino acid sequence having a sequence identity of 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, further preferably 95% or more, further preferably 97% or more, further preferably 98% or more, further preferably 99% or more with respect to the amino acid sequence of SEQ ID NO: 46 and having a function of increasing the productivity of 3HA and / or 3OA by increasing the expression amount thereof can also be used as MdtD.

[0055] RhtB (also known as YigK) is a protein called homoserine / homoserine lactone efflux protein, and specific examples thereof include RhtB from Escherichia coli str. K-12 substr. MG1655 (NCBI Protein ID: YP_026265, sequence number 48), and genes encoding RhtB include rhtB from Escherichia coli str. K-12 substr. MG1655 (NCBI Gene ID: 948316, sequence number 49). In addition, if a protein is composed of an amino acid sequence in which one or more amino acids are substituted, deleted, inserted, and / or added to the amino acid sequence of sequence number 48, and has a function of increasing the productivity of 3HA and / or 3OA by increasing the expression level thereof, the protein can be used as RhtB. Here, the range of "1 or more" is preferably within 10, more preferably within 5, further preferably within 4, and particularly preferably within 1 or 2. In addition, a protein consisting of an amino acid sequence having a sequence identity of 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, further preferably 95% or more, further preferably 97% or more, further preferably 98% or more, further preferably 99% or more with respect to the amino acid sequence of SEQ ID NO: 48 and having a function of increasing the productivity of 3HA and / or 3OA by increasing the expression amount thereof can also be used as RhtB.

[0056] MFS40 is a protein belonging to the major facilitator superfamily (MFS), and as a specific example, MFS40 from Aspergillus oryzae RIB40 strain (NCBI Protein ID: XP_001826887, sequence number 50) can be cited, and as a gene encoding MFS40, the MFS40 gene from Aspergillus oryzae RIB40 strain (NCBI Reference Sequence: XM_001826835.2, sequence number 51) can be cited. In addition, if it is composed of an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added in the amino acid sequence of sequence number 50, and has a function of increasing the productivity of 3HA and / or 3OA by increasing its expression level, the protein can be used as MFS40. Here, the range of "1 or more" is preferably within 10, more preferably within 5, further preferably within 4, and particularly preferably within 1 or 2. In addition, a protein consisting of an amino acid sequence having a sequence identity of 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, further preferably 95% or more, further preferably 97% or more, further preferably 98% or more, further preferably 99% or more with respect to the amino acid sequence of SEQ ID NO: 50 and having a function of increasing the productivity of 3HA and / or 3OA by increasing the expression amount thereof can also be used as MFS40.

[0057] Homologs of MdtD, RhtB, and MFS40 are proteins that are presumed to have high sequence identity with the amino acid sequence of each protein and to have functions or structures similar to those of each protein. The following homologs can be used: MdtD from Escherichia coli str. K-12 substr. MG1655 (NCBI Protein ID: NP_416581, SEQ ID NO: 46), RhtB from Escherichia coli str. K-12 substr. MG1655 (NCBI Protein ID: YP_026265, SEQ ID NO: 48), and MdtD from Aspergillus oryzae MFS40 of the RIB40 strain (NCBI Protein ID: XP_001826887, sequence number 50) has a sequence identity of specifically 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, and particularly preferably 95% or more, and has the function of increasing the productivity of 3HA and / or 3OA by increasing their expression levels. In addition, for example, by using the amino acid sequence of MdtD as a query sequence, performing a BLAST (Basic Local Alignment Search Tool) search on public databases such as NCBI (National Center for Biotechnology Information) or KEGG (Kyoto Encyclopedia of Genes and Genomes), and referring to the gene encoding the retrieved sequence, their homologs can be easily obtained. In addition, it can also be obtained by using oligonucleotides made based on the base sequence of a gene encoding MdtD or its homolog as primers and performing PCR using genomic DNA from other organisms as a template.

[0058] Preferably, the gene encoding the above-mentioned protein suitable as a carrier for excretion of an organophosphate compound is introduced as a foreign gene into a microbial host and expressed (see Examples below).

[0059] The method for enhancing the enzyme activity of the reaction (reaction A) of producing 3-oxoadipyl-CoA and CoA from acetyl-CoA and succinyl-CoA in a microorganism having the ability to produce 3HA and / or 3OA is well known per se and can be preferably performed according to the method described in WO2017 / 209102, for example.

[0060] Examples of the enzyme having an activity of catalyzing the reaction of generating 3-oxoadipyl-CoA and CoA from succinyl-CoA and acetyl-CoA include acetyl-CoA acetyltransferase, β-ketoacyl-CoA acyltransferase, 3-oxoadipyl-CoA acyltransferase, β-ketoadipyl-CoA acyltransferase, acetyl-CoA C-acetyltransferase, acetoacetyl-CoA thiolase, β-acetoacetyl-CoA thiolase, 2-methylacetoacetyl-CoA thiolase, 3-oxothiolase, acetyl-CoA thiolase, acetyl-CoA acetyltransferase, acetyl-CoA:N acetyltransferase, acetyl-CoA C acyltransferase, β-ketothiolase, 3-ketoacyl-CoA thiolase, β-ketoacyl-CoA thiolase, β-ketoacyl-CoA thiolase, β-ketoadipyl-CoA thiolase, β-ketoadipyl-CoA thiolase, 3-ketoacyl-CoA thiolase, 3-ketoacyl thiolase, 3-ketoacyl thiolase, 3-ketothiolase, 3-oxoacyl-CoA thiolase, 3-oxoacyl-CoA thiolase, 6-oxoacyl-C oA thiolase, acetoacetyl-CoA β-ketothiolase, acetyl-CoA acyltransferase, ketoacyl-CoA acyltransferase, ketoacyl-CoA thiolase, long-chain 3-oxoacyl-CoA thiolase, oxoacyl-CoA thiolase, pro-3-ketoacyl-CoA thiolase, 3-oxoadipyl-CoA thiolase, 3-oxo-5,6-didehydrocycloheptyl-CoA thiolase and the like. In addition, although not particularly limited in classification based on EC number, acyltransferases classified in EC2.3.1.- are preferred, and specific examples thereof include enzymes classified in EC2.3.1.174, EC2.3.1.9, EC2.3.1.16, and EC2.3.1.223.

[0061] In addition, whether a protein encoded by a gene sequence whose function is unknown corresponds to the above enzyme can be estimated by performing a BLAST search on a website such as NCBI (National Center for Biotechnology Information) to determine whether it corresponds to the enzyme.

[0062] Preferred specific examples of these enzymes include enzymes derived from the following microorganisms: microorganisms of the genus Acinetobacter, such as Acinetobacter baylyi and Acinetobacter radioresistens; microorganisms of the genus Aerobacter, such as Aerobacter cloacae; microorganisms of the genus Alcaligenes, such as Alcaligenes faecalis; microorganisms of the genus Bacillus, such as Bacillus badius, Bacillus megaterium, and Bacillus roseus; microorganisms of the genus Brevibacterium, such as Brevibacterium iodinum; microorganisms of the genus Brevibacterium, such as Corynebacterium acetoacidophilum and Corynebacterium acetoglutamicum; acetoglutamicum), Corynebacterium ammoniagenes, Corynebacterium glutamicum, etc.; Cupriavidus genus microorganisms such as Cupriavidus metallidurans, Cupriavidus necator, Cupriavidus numazuensis, Cupriavidusoxalaticus, etc.; Delftia genus microorganisms such as Delftia acidovorans; Escherichia coli, Escherichia fergusonii, etc.; Hafnia genus microorganisms such as Hafniaalvei; Microbacterium ammoniaphilus ammoniaphilum and other Microbacterium microorganisms; Nocardioides albus and other Nocardioides microorganisms;Planomicrobium okeanokoites and other Planomicrobium microorganisms; Pseudomonas azotoformans, Pseudomonas chlororaphis, Pseudomonas fluorescens, Pseudomonas fragi, Pseudomonas putida, Pseudomonas reptilivora, Pseudomonas taetrolens and other Pseudomonas microorganisms; Rhizobium radiobacter and other Rhodosporidium toruloides and other Rhodosporidium microorganisms; Saccharomyces cerevisiae and other Saccharomyces cerevisiae and other Serratia microorganisms; Serratia entomophila, Serratia ficaria, Serratia fonticola, Serratia grimesii, Serratia nematodiphila, Serratia odorifera, Serratia plymuthica and other Serratia microorganisms; Shimwellia blattae and other Shimwellia microorganisms; Streptomyces vinaceus, Streptomyces karnatakensis, Streptomyces olive olivaceus, Streptomyces vinaceus, etc.; Yarrowia lipolytica, etc.;Yersinia microorganisms such as Yersinia ruckeri, preferably include: PaaJ from Escherichia coli str.K-12 substr.MG1655 strain (NCBI Protein ID: NP_415915), PcaF from Pseudomonas putida KT2440 strain (NCBI Protein ID: NP_743536), PcaF from Corynebacterium glutamicum ATCC13032 strain (NCBI Protein ID: CAF21057), etc.;

[0063] In addition, it is preferred that in the genetically modified microorganism of the present invention, according to the descriptions of WO2019 / 107516 and WO2021 / 187533, the activity of the enzyme that catalyzes the reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA (reaction B), the reaction of producing 3-hydroxyadipic acid from 3-hydroxyadipyl-CoA (reaction C), and / or the reaction of producing 3-oxoadipate from 3-oxoadipyl-CoA (reaction D) is enhanced.

[0064] Examples of the enzyme that catalyzes the reaction (reaction B) of reducing 3-oxoadipyl-CoA to generate 3-hydroxyadipyl-CoA include enzymes classified under EC 1.1.1.35 as 3-hydroxyacyl-CoA dehydrogenases and enzymes classified under EC 1.1.1.157 as 3-hydroxybutyryl-CoA dehydrogenases. Specifically, as enzymes that catalyze the reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA, PaaH from Pseudomonasputida KT2440 strain (NCBI Protein ID: NP_745425.1), PaaH from Escherichia coli str. K-12 substr. MG1655 strain (NCBI Protein ID: NP_415913.1), DcaH from Acinetobacter baylyi ADP1 strain (NCBI Protein ID: CAG68533.1), PaaH from Serratia plymuthica NBRC102599 strain (NCBI Protein ID: WP_063197120), and a polypeptide from Serratia nematodiphila DSM21420 strain (NCBI Protein ID: WP_033633399.1) can be cited.

[0065] As the enzyme that catalyzes the reaction of producing 3-hydroxyadipic acid from 3-hydroxyadipyl-CoA (reaction C) and / or the reaction of producing 3-oxoadipate from 3-oxoadipyl-CoA (reaction D), CoA transferase or acyl-CoA hydratase can be used, and CoA transferase is preferred.

[0066] CoA transferase refers to an enzyme having a catalytic activity (CoA transferase activity) of a reaction in which acyl-CoA and succinic acid are substrates to generate carboxylic acid and succinyl-CoA. As CoA transferase, there is no particular limitation on the classification based on the EC number, and CoA transferases classified in EC2.8.3.-, CoA transferases classified in EC2.8.3.6 or acyl-CoA transferases can be listed, and as a specific example, PcaI (NCBI Protein ID: NP_746081) and PcaJ (NCBI Protein ID: NP_746082) from Pseudomonas putida KT2440 strain can be preferably used.

[0067] In the present invention, there is no particular limitation on the method of increasing the expression level of the organophosphate compound excretion vector or strengthening the various enzyme activities related to the metabolism of 3HA and / or 3OA. The method of increasing the expression level of various enzyme activities or functional polypeptides by introducing genes encoding various enzymes or functional polypeptides from outside the host microorganism into the microorganism; or increasing the copy number of the gene; or changing the promoter region or ribosome binding sequence upstream of the gene is preferred. These methods can be performed alone or in combination. The introduced gene can be artificially synthesized based on the amino acid sequence of the enzyme present in the database, or it can be isolated from nature. In the case of artificial synthesis, the usage frequency of the codons corresponding to each amino acid can be changed according to the introduced host microorganism. There is no particular limitation on the method of introducing nucleic acid, and a method of assembling the nucleic acid into an expression vector that can replicate autonomously in a microorganism and introducing it into a host microorganism, or a method of assembling the nucleic acid in the genome of a microorganism, etc. can be used.

[0068] The genes introduced may be one or more than one. In addition, gene introduction and enhancement of gene expression may be combined.

[0069] In the present invention, when a nucleic acid encoding a polypeptide to be expressed is assembled in an expression vector or a host microorganism genome, the expression vector or the genome assembly nucleic acid is preferably composed of a promoter, a ribosome binding sequence, a nucleic acid encoding a polypeptide to be expressed, and a transcription termination sequence. In addition, a gene that controls promoter activity may also be included.

[0070] The promoter used in the present invention is not particularly limited as long as it can express the enzyme in the host microorganism, and examples thereof include gap promoter, trp promoter, lac promoter, tac promoter, T7 promoter and the like.

[0071] In the present invention, when an expression vector is used to introduce a nucleic acid or enhance the expression of a polypeptide, it is not particularly limited as long as it can replicate autonomously in the microorganism. Examples thereof include pBBR1MCS vector, pBR322 vector, pMW vector, pET vector, pRSF vector, pCDF vector, pACYC vector, and derivatives of the above vectors.

[0072] In the present invention, when nucleic acid is introduced or polypeptide expression is enhanced using nucleic acid for genome assembly, site-specific homologous recombination is used for introduction. The method of site-specific homologous recombination is not particularly limited, and examples thereof include: a method using λRed recombinase and FLP recombinase (Proc NatI Acad Sci USA. 2000Jun 6; 97(12): 6640-6645); a method using λRed recombinase and sacB gene (Biosci Biotechnol Biochem. 2007Dec; 71(12): 2905-11.).

[0073] The method for introducing the expression vector or nucleic acid for genome assembly is not particularly limited as long as it is a method for introducing nucleic acid into a microorganism, and examples thereof include: the calcium ion method (Journal of Molecular Biology, 53, 159 (1970)); the electroporation method (NM Calvin, PC Hanawalt. J. Bacteriol, 170 (1988), pp. 2796-2801);

[0074] Examples of microorganisms that have the ability to produce 3HA and / or 3OA include the following microorganisms.

[0075] Escherichia fergusonii, Escherichia coli, and other Escherichia coli.

[0076] Serratia spp., such as Serratia grimesii, Serratia ficaria, Serratia fonticola, Serratia odorifera, Serratia plymuthica, Serratia entomophila or Serratia nematodiphila.

[0077] Pseudomonas species include Pseudomonas chlororaphis, Pseudomonas putida, Pseudomonas azotoformans, Pseudomonas chlororaphis subsp. aureofaciens, Pseudomonas fragi, Pseudomonas fluorescens, Pseudomonas reptilivora and Pseudomonas azotoformans.

[0078] Hafnia alvei and other Hafnia species.

[0079] Corynebacterium species such as Corynebacterium acetoacidophilum, Corynebacterium acetoglutamicum, Corynebacterium ammoniagenes, and Corynebacterium glutamicum.

[0080] Bacillus species such as Bacillus badius, Bacillus megaterium, and Bacillus roseus.

[0081] Streptomyces genus such as Streptomyces vinaceus, Streptomyces karnatakensis and Streptomyces olivaceus.

[0082] Cupriavidus metallidurans, Cupriavidus necator, Cupriavidus oxalaticus and other Cupriavidus species.

[0083] Acinetobacter species such as Acinetobacter baylyi and Acinetobacter radioresistance tens.

[0084] Alcaligenes faecalis and other Alcaligenes species.

[0085] Nocardioides albus and other Nocardioides species.

[0086] Brevibacterium iodinum and other Brevibacterium species.

[0087] Delftia acidovorans and other Delftia species.

[0088] Shimwellia blattae and other Shimwellia genus.

[0089] Aerobacter cloacae and other Aerobacter species.

[0090] Rhizobium species such as Rhizobium radiobacter.

[0091] Planomicrobium okeanokoites and other Planomicrobium genera.

[0092] Yarrowia lipolytica and other Yarrowia species.

[0093] Rhodosporidium toruloides and other Rhodosporidium toruloides species.

[0094] Microbacterium ammoniaphilum and other Microbacterium species.

[0095] Saccharomyces cerevisiae and other yeast species.

[0096] Yersinia ruckeri and other Yersinia spp.

[0097] Among the microorganisms having the ability to produce 3HA and / or 3OA, the present invention preferably utilizes microorganisms belonging to the genus Escherichia coli or Serratia.

[0098] When the genetically modified microorganism of the present invention itself does not have the ability to produce 3HA and / or 3OA, according to the records of WO2017 / 209102 and WO2019 / 107516, these production capabilities can be conferred by appropriately combining nucleic acids encoding enzymes that catalyze reactions A, B, and C and introducing them into the microorganism.

[0099] The microorganisms that can be used as hosts for obtaining genetically modified microorganisms in the present invention are not particularly limited as long as they are microorganisms that can be genetically modified. Preferably, they are microorganisms belonging to the genera Escherichia coli, Serratia, Hafnia, Pseudomonas, Corynebacterium, Bacillus, Streptomyces, Cupriavidus, Acinetobacter, Alcaligenes, Brevibacterium, Delftia, Shimwellia, Aerobacter, Rhizobium, Thermobifida, Clostridium, Schizosaccharomyces, Kluyveromyces, Pichia, and Candida, more preferably microorganisms belonging to the genera Escherichia coli, Serratia, Hafnia, and Pseudomonas, and particularly preferably microorganisms belonging to the genera Escherichia coli or Serratia.

[0100] Fermentation raw materials refer to raw materials that can be metabolized by the genetically modified microorganism. "Metabolism" refers to the conversion of a chemical compound absorbed by the microorganism from outside the cell or generated from other chemical compounds in the cell into other chemical compounds through an enzyme reaction. As a carbon source, sugars can be preferably used. Specific examples of sugars include: monosaccharides such as glucose, sucrose, fructose, galactose, mannose, xylose, arabinose, etc.; disaccharides and polysaccharides formed by the combination of these monosaccharides; and starch saccharification liquid, molasses, cellulose-containing biomass saccharification liquid, etc. containing these sugars.

[0101] The carbon sources listed above can be used alone or in combination, and are particularly preferably cultured in a medium containing glucose. In the addition of the carbon source, the concentration of the carbon source in the medium is not particularly limited and can be appropriately set according to the type of the carbon source, etc. The preferred concentration of glucose is 5 to 300 g / L.

[0102] As the nitrogen source for culturing the genetically modified microorganism, for example, ammonia gas, ammonia water, ammonium salts, urea, nitrates, other organic nitrogen sources used as auxiliary materials, such as oil residues, soybean hydrolyzate, casein decomposition products, other amino acids, vitamins, corn steep liquor, yeast or yeast extract, meat extract, peptides such as peptone, various fermentation cells and their hydrolyzates, etc. can be used. The concentration of the nitrogen source in the culture medium is not particularly limited, but is preferably 0.1 to 50 g / L.

[0103] As inorganic salts used for culturing the genetically modified microorganism, for example, phosphates, magnesium salts, calcium salts, iron salts, manganese salts, etc. can be appropriately added and used.

[0104] The culture conditions for the genetically modified microorganisms used to produce 3HA and / or 3OA can be appropriately adjusted or selected and set according to the type of the genetically modified microorganisms and external conditions, such as the culture medium composed of the above components, culture temperature, stirring speed, pH, ventilation volume, inoculation amount, etc.

[0105] The pH range during the culture is not particularly limited as long as the genetically modified microorganism can grow, but is preferably pH 5 to 8, more preferably pH 5.5 to 6.8.

[0106] The range of aeration conditions during culture is not particularly limited as long as 3HA and / or 3OA can be produced, but in order to allow the microbial variant to grow well, it is preferred that oxygen remain in the liquid phase or gas phase in the culture container at least at the beginning of culture.

[0107] When foaming occurs during liquid culture, an antifoaming agent such as mineral oil, silicone oil, or surfactant may be added to the appropriate culture medium.

[0108] After 3HA and / or 3OA are produced in the culture of the microorganism until a recoverable amount, the produced product can be recovered. For the recovery of the produced product, for example, the culture can be stopped at a time point when the cumulative amount is appropriately increased, and the product can be separated according to the general method of extracting the fermentation product from the culture. Specifically, after the bacterial cells are separated by centrifugation, filtration, etc., the product is separated from the culture by column chromatography, ion exchange chromatography, activated carbon treatment, crystallization, membrane separation, distillation, etc. More specifically, it can be listed as: a method of recovering the precipitate by adding an acid component to the salt of the product; a method of concentrating the culture by a reverse osmosis membrane or a rotary evaporator to remove water, increase the concentration of the product, and then precipitate the crystals of the product and / or the salt of the product by cooling crystallization or adiabatic crystallization, and then obtain the crystals of the product and / or the salt of the product by centrifugation or filtration; a method of adding alcohols to the culture to make the product an ester, recovering the ester of the product by distillation, and then obtaining the product by hydrolysis, etc., but not limited to these. In addition, these recovery methods can be appropriately selected and optimized according to the physical properties of the product.

[0109] Adipic acid can be produced by reacting 3HA and / or 3OA obtained in the present invention with hydrogen in the presence of a hydrogenation catalyst (hydrogenation).

[0110] The hydrogenation catalyst preferably contains a transition metal element, specifically, preferably contains one or more selected from the group consisting of palladium, platinum, ruthenium, rhodium, rhenium, nickel, cobalt, iron, iridium, osmium, copper and chromium, more preferably contains one or more selected from the group consisting of palladium, platinum, nickel, cobalt, iron, copper and chromium.

[0111] From the viewpoints of the amount of metal that can be used sparingly, the active surface of the catalyst increasing, etc., the hydrogenation catalyst is preferably loaded on a carrier for use. The loading of the hydrogenation catalyst on the carrier can be carried out by known methods such as an impregnation method, a precipitation method, and a gas phase loading method. As the carrier, carbon, a polymer, a metal oxide, a metal sulfide, a zeolite, a clay, a heteropolyacid, a solid phosphoric acid, a hydroxyapatite, etc. can be listed.

[0112] The hydrogen to be reacted with 3HA and / or 3OA may be added to the reactor at once or successively. There is no particular limitation on the partial pressure of hydrogen, but when it is too low, the reaction time becomes long. On the other hand, when the partial pressure of hydrogen is too high, it is not ideal in terms of equipment safety. Therefore, it is preferably 0.1 MPa to 10 MPa (gauge pressure) at room temperature, more preferably 0.3 MPa to 5 MPa (gauge pressure), and further preferably 0.5 MPa to 3 MPa (gauge pressure).

[0113] The reaction may be carried out in a batch tank reactor, a semi-batch tank reactor, a continuous tank reactor, a continuous tubular reactor, or a trickle bed tubular reactor. When a solid hydrogenation catalyst is used, the reaction may be carried out in a suspended bed, a fixed bed, a moving bed, or a fluidized bed.

[0114] The reaction temperature of hydrogenation is not particularly limited, but when it is too low, the reaction rate slows down, and when the reaction temperature is too high, the energy consumption increases, which is not preferred. From such a viewpoint, the reaction temperature is preferably 100 to 350°C, more preferably 120 to 300°C, further preferably 130 to 280°C, further preferably 140 to 250°C, further preferably 150 to 230°C, further preferably 160 to 220°C.

[0115] In the atmosphere in the reactor, inert gases such as nitrogen, helium, and argon may coexist in addition to hydrogen. However, since the oxygen concentration is related to the deterioration of the hydrogenation catalyst and the generation of explosive gas, it is preferably 5% by volume or less. In addition, from the viewpoint of the stability of 3HA and / or 3OA and adipic acid, the amount of ammonia is preferably 5% by weight or less, more preferably 3% by weight or less, and further preferably 0% by weight (i.e., reaction in the absence of ammonia).

[0116] The hydrogenation of 3HA and / or 3OA is preferably carried out in the presence of a solvent.

[0117] As the hydrogenation solvent, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, pentane, hexane, cyclohexane, heptane, octane, decane, dimethyl ether, diethyl ether, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, tetrahydrofuran, dioxane, methyl acetate, ethyl acetate, n-propyl acetate, n-butyl acetate, γ-butyrolactone, N-methylpyrrolidone, dimethyl sulfoxide, aqueous solvents, etc. can be used. A mixed solvent of two or more of them can also be used. However, from the viewpoint of economy and environmental protection, it is preferred to use an aqueous solvent.

[0118] In the present invention, an aqueous solvent refers to a mixed solvent obtained by mixing water or a water-miscible organic solvent mainly composed of water. "Mainly composed of water" means that the proportion of water in the mixed solvent exceeds 50% by volume, preferably 70% by volume or more, and more preferably 90% by volume or more.

[0119] Examples of the water-miscible organic solvent include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, 1,2-dimethoxyethane, diglyme, tetrahydrofuran, dioxane, γ-butyrolactone, N-methylpyrrolidone, dimethyl sulfoxide, dimethylformamide, dimethylacetamide, and acetone.

[0120] The pH of the aqueous solvent is not particularly limited, but is preferably pH 2 to 13, more preferably pH 3 to 11, and even more preferably pH 4 to 10 in consideration of inhibition of catalyst degradation, inhibition of by-product generation, and corrosion to a reaction apparatus.

[0121] When a solvent other than primary alcohol and secondary alcohol is used as a hydrogenation solvent, the corresponding adipic acid, adipic acid salt, and adipic acid ester can be generated from the carboxylic acid, carboxylate, and carboxylate of 3-hydroxyadipic acid and / or α-hydrogenated adipic acid, respectively. When a solvent containing a primary alcohol or secondary alcohol such as methanol, ethanol, n-propanol, isopropanol, n-butanol, and isobutanol is used as a hydrogenation solvent, a mixture of adipic acid, adipic acid salt, adipic acid monoester, and adipic acid diester is obtained after the reaction. It should be noted that in this specification, the carboxylic acid, carboxylate, and carboxylate of adipic acid and their mixtures are collectively referred to as "adipic acid".

[0122] The carboxylic acid of the adipic acid obtained in the present invention can be further subjected to an esterification reaction to be converted into an adipic acid ester. The esterification method is not particularly limited, and examples thereof include dehydration condensation of carboxylic acid and alcohol using an acid catalyst or a condensation agent, and methods using an alkylating agent such as diazomethane or a haloalkyl.

[0123] The adipic acid obtained in the present invention can be separated and purified by common unit operations such as centrifugation, filtration, membrane filtration, distillation, extraction, crystallization, and drying.

[0124] Adiponitrile can be produced from the adipic acid obtained in the present invention by a known method (for example, Japanese Patent Publication No. 61-24555). Hexamethylenediamine can be produced by hydrogenating the obtained adiponitrile by a known method (for example, Japanese Patent Publication No. 2000-508305).

[0125] Polyamide can be produced by polycondensing the adipic acid obtained in the present invention with diamine using a known method (for example, see Fukumoto Shuedan, "Polyamide Resin Handbook", Nikkan Kogyo Publishing (January 1998)). Specifically, polyamide 46, polyamide 56, and polyamide 66 can be produced by using 1,4-butanediamine, 1,5-pentanediamine, and hexamethylenediamine as diamines, respectively.

[0126] Polyamide fibers can be produced by processing polyamide by known methods (e.g., International Publication No. 2019 / 208427). The polyamide fibers obtained in this way can be used for clothing purposes such as underwear, sportswear, and casual wear; and industrial materials such as airbags and tire cords.

[0127] In addition, polyamide molded products can be manufactured by molding polyamide by a known method (for example, International Publication No. 2021 / 006257). The polyamide molded products obtained in this way can be used for automobile parts, electrical parts, electronic parts, building parts, various containers, daily necessities, daily necessities, and sanitary products.

[0128] Example

[0129] Hereinafter, the present invention will be specifically described with reference to examples.

[0130] Reference Example 1

[0131] Preparation of plasmid for expressing enzyme catalyzing reaction of generating 3OA-CoA and CoA from acetyl-CoA and succinyl-CoA (reaction A); reaction of generating 3HA-CoA from 3OA-CoA (reaction B), reaction of generating 3HA from 3HA-CoA (reaction C), and / or reaction of generating 3OA from 3OA-CoA (reaction D)

[0132] The vector pBBR1MCS-2 (ME Kovach, (1995), Gene 166: 175-176) with a kanamycin resistance gene that can replicate autonomously in Escherichia coli was cut with XhoI to obtain pBBR1MCS-2 / XhoI. In order to assemble a constitutive expression promoter in this vector, primers (sequence numbers 6 and 7) for amplifying the upstream region 200b (sequence number 5) of gapA (NCBI-GeneID: NC_000913.3) were designed using the genomic DNA of Escherichia coli str. K-12 substr. MG1655 as a template, and a PCR reaction was performed according to a conventional method. The obtained fragment was connected to pBBR1MCS-2 / XhoI using the "In-Fusion HD Cloning Kit" (manufactured by TakaraBio Co., Ltd.) and introduced into the Escherichia coli strain DH5α. The plasmid was extracted from the obtained recombinant Escherichia coli strain, and the plasmid whose base sequence was confirmed according to the conventional method was set to pBBR1MCS-2::Pgap. Then, pBBR1MCS-2::Pgap was cut using ScaI to obtain pBBR1MCS-2::Pgap / ScaI. In order to amplify the gene encoding the enzyme that catalyzes reaction A, primers (sequence numbers 9 and 10) for amplifying the full length of the acyltransferase gene pcaF (NCBI-GeneID:1041755, sequence number 8) were designed using the genomic DNA of the Pseudomonas putida KT2440 strain as a template, and PCR reactions were performed according to conventional methods. The obtained fragment and pBBR1MCS-2::Pgap / ScaI were connected using the "In-Fusion HD Cloning Kit" (manufactured by Takara Bio Co., Ltd.) and introduced into the Escherichia coli strain DH5α. The plasmid was extracted from the obtained recombinant strain, and the plasmid whose base sequence was confirmed by conventional methods was set to pBBR1MCS-2::AT. Then, pBBR1MCS-2::AT was cut using HpaI to obtain pBBR1MCS-2::AT / HpaI. In order to amplify the gene encoding the enzyme that catalyzes reaction C and / or reaction D, the genomic DNA of Pseudomonasputida KT2440 strain was used as a template, and primers (sequence numbers 13 and 14) were designed for amplifying the full-length continuous sequence containing the CoA transferase genes pcaI and pcaJ (NCBI-GeneID: 1046613, 1046612; sequence numbers: 11, 12), and PCR reaction was carried out according to conventional methods.The obtained fragment was ligated to pBBR1MCS-2::AT / HpaI using the In-Fusion HD Cloning Kit and introduced into the E. coli strain DH5α. The plasmid was extracted from the obtained recombinant strain and the base sequence was confirmed by a conventional method, and the plasmid was designated as pBBR1MCS-2::ATCT.

[0133] pBBR1MCS-2::ATCT was cut using ScaI to obtain pBBR1MCS-2::ATCT / ScaI. In order to amplify the nucleic acid encoding the polypeptide of sequence number 15 that catalyzes reaction B, primers (sequence numbers 17 and 18) for amplifying the full length of the enzyme gene (sequence number 16) that catalyzes reaction B were designed using the genomic DNA of Serratia marcescens ATCC13880 strain as a template, and a PCR reaction was performed according to conventional methods. The obtained fragment and pBBR1MCS-2::ATCT / ScaI were connected using the "In-Fusion HD Cloning Kit" (manufactured by TakaraBio Co., Ltd.) and introduced into the Escherichia coli strain DH5α. The plasmid was extracted from the obtained recombinant strain, and the plasmid whose base sequence was confirmed according to conventional methods was set to pBBR1MCS-2::ATCTOR.

[0134] Next, the kanamycin resistance gene of pBBR1MCS-2::ATCTOR was replaced with a chloramphenicol resistance gene. Using pHSG396 (manufactured by Takara Bio Co., Ltd.) as a template, PCR was performed using the nucleic acids of sequence numbers 19 and 20 as primers to amplify the chloramphenicol resistance gene. The PCR fragment was connected to the fragment obtained by cutting pBBR1MCS-2::ATCTOR using In-Fusion HD Cloning Kit and introduced into the Escherichia coli DH5α strain. The plasmid was extracted from the resulting recombinant strain, and the plasmid whose base sequence was confirmed according to a conventional method was set to pBBRc::ATCTOR.

[0135] Reference Example 2

[0136] Preparation of plasmid expressing YhhS

[0137] In order to amplify the gene encoding YhhS and its surrounding area, PCR was performed using the genomic DNA of Escherichia colistr.K-12substr.MG1655 strain as a template and the nucleic acids of sequence numbers 21 and 22 as primers to amplify the full length of the yhhS gene (sequence number 2) and the nucleic acid 0.5 kb upstream and downstream thereof. The PCR fragment was connected to the fragment obtained by cutting the expression vector pMW119 (manufactured by Nippon Gene Co., Ltd.) that can replicate autonomously in Escherichia coli using KpnI using In-Fusion HD Cloning Kit, and introduced into the Escherichia coli DH5α strain. The plasmid was extracted from the obtained recombinant strain, and the plasmid whose base sequence was confirmed according to the conventional method was set to pMW::EcYHHS.

[0138] Reference Example 3

[0139] Preparation of Escherichia coli microorganism mutants with YhhS function defective

[0140] In order to delete the function of YhhS of a microorganism of the genus Escherichia coli, a mutant of a microorganism of the genus Escherichia coli in which the gene encoding YhhS was deleted was prepared.

[0141] The method for deletion of the target gene was based on the method described in Proc Natl Acad Sci USA. 2000 Jun 6; 97(12): 6640-6645.

[0142] Using pKD4 as a template and oligo DNAs of sequence numbers 23 and 24 as primers for PCR, a PCR fragment with a sequence length of 1.6 kb for yhhS deficiency was obtained. The FRT recombinase expression plasmid, pKD46, was introduced into the Escherichia coli str.K-12substr.BW25113 strain to obtain an ampicillin-resistant strain. The obtained strain was inoculated in 5 mL of LB medium containing 100 μg / mL ampicillin and cultured at 37°C with shaking for 1 day. 0.5 mL of the culture solution was inoculated in 50 mL of LB medium containing 100 μg / mL ampicillin and 50 mM arabinose, and cultured at 37°C with rotation for 2 hours. After the culture solution was ice-cooled for 20 minutes, the bacteria were washed 3 times with 10% (w / w) glycerol. Use 100 μL of 10% (w / w) glycerol to suspend the washed pellet, mix with 5 μL of PCR fragment, and cool in the electroporation tank for 10 minutes. After electroporation (3kV, 200Ω, 25μF) using "Genepulser" (manufactured by Bio-rad), immediately add 1mL of SOC medium and culture with vibration at 37°C for 2 hours. All are coated on LB agar medium containing 25μg / mL kanamycin and incubated at 37°C for 1 day. Colony direct PCR was performed using the obtained kanamycin-resistant strain, and the defect of the target gene and the insertion of the kanamycin resistance gene were confirmed based on the length of the band. The primers used oligo DNAs of sequence numbers 25 and 26, 26 and 27, respectively. The obtained Escherichia coli microbial variant with defective YhhS function was set to EcΔyhhS.

[0143] Reference Example 4

[0144] Preparation of 3HA and / or 3OA producing strains and control strains with YhhS function deficiency

[0145] The plasmids pBBRc::ATCTOR and pMW119 prepared in Reference Example 1 were introduced into EcΔyhhS prepared in Reference Example 3 to prepare a 3HA and / or 3OA producing strain in which the YhhS function was deficient.

[0146] EcΔyhhS and E.coli str.K-12substr.BW25113 were inoculated into 5 mL of LB medium and cultured at 37°C with shaking for 1 day. 0.5 mL of the culture solution was inoculated into 5 mL of LB medium and cultured at 37°C with shaking for 2 hours. After cooling the culture solution on ice for 20 minutes, the bacteria were washed three times with 10% (w / w) glycerol. The washed pellet was suspended with 100 μL of 10% (w / w) glycerol, mixed with 1 μL of pBBRc::ATCTOR and pMW119, and then cooled in an electroporation tank for 10 minutes. After electroporation (3 kV, 200 Ω, 25 μF) using "Gene pulser" (manufactured by Bio-rad), 1 mL of SOC medium was immediately added and cultured at 37°C with shaking for 1 hour. 50 μL was spread on LB agar medium containing 15 μg / mL chloramphenicol and 100 μg / mL ampicillin, and incubated at 37° C. for 1 day. The obtained strain was designated as EcΔyhhS / 3HA_pMW.

[0147] In addition, as a control strain, pBBRc::ATCTOR and pMW119 were introduced into Escherichia coli str.K-12 substr.BW25113 by the above method to obtain a 3HA and / or 3OA producing strain (EcWT / 3HA_pMW) in which the YhhS function was not defective.

[0148] Comparative Example 1

[0149] 3HA production test of control strain

[0150] A platinum ring of the control strain (EcWT / 3HA_pMW) was inoculated into 5 mL of medium I (10 g / L Bacto tryptone (manufactured by Difco Laboratories), 5 g / L Bacto yeast extract (manufactured by Difco Laboratories), 5 g / L sodium chloride, 15 μg / mL chloramphenicol, 100 μg / mL ampicillin) (φ18 mm glass test tube, aluminum plug) adjusted to pH 7 and incubated at 30°C for 120 min. -1The culture was shaken for 24 hours. 0.25 mL of the culture solution was added to 5 mL of medium II (50 g / L glucose, 1 g / L ammonium sulfate, 50 mM potassium phosphate, 0.025 g / L magnesium sulfate, 0.0625 mg / L iron sulfate, 2.7 mg / L manganese sulfate, 0.33 mg / L calcium chloride, 1.25 g / L sodium chloride, 2.5 g / L Bacto tryptone, 1.25 g / L Bacto yeast extract, 15 μg / mL chloramphenicol, 100 μg / mL ampicillin) (φ18 mm glass test tube, aluminum plug) adjusted to pH 6.5 and cultured at 30°C.

[0151] The supernatant after centrifugal separation of the bacterial cells from the obtained culture solution was treated with a membrane using "Millex-GV" (0.22 μm, PVDF, manufactured by Merck), and the permeate was analyzed using LC-MS / MS under the following conditions to quantify the concentration of 3HA and other products accumulated in the culture supernatant and the sugars remaining in the culture medium that were not utilized. Furthermore, the yield of 3HA calculated based on the results and using the following formula (2) is shown in Table 1.

[0152] Quantitative analysis of 3HA by LC-MS / MS

[0153] HPLC: 1290 Infinity (manufactured by Agilent Technologies)

[0154] Column: Synergi hydro-RP (manufactured by Phenomenex), length 100 mm, inner diameter 3 mm, particle size 2.5 μm

[0155] Mobile phase: 0.1% formic acid aqueous solution / methanol = 70 / 30

[0156] Flow rate: 0.3mL / min

[0157] Column temperature: 40°C

[0158] LC detector: 1260DAD VL+ (210nm)

[0159] MS / MS: Triple-Quad LC / MS (manufactured by Agilent Technologies)

[0160] Ionization method: ESI negative mode.

[0161] Quantitative analysis of sugars using HPLC

[0162] HPLC: Shimazu Prominence (manufactured by Shimadzu Corporation)

[0163] Column: Shodex Sugar SH1011 (manufactured by Showa Denko K.K.), length 300 mm, inner diameter 8 mm, particle size 6 μm

[0164] Mobile phase: 0.05M sulfuric acid aqueous solution

[0165] Flow rate: 0.6mL / min

[0166] Column temperature: 65°C

[0167] Detector: RID-10A (manufactured by Shimadzu Corporation).

[0168] 3HA yield (%) = 3HA production (mol) / sugar consumption (mol) × 100···Formula (2).

[0169] Reference Example 5

[0170] 3HA production test of 3HA and / or 3OA producing strains with YhhS function defective

[0171] Using the 3HA and / or 3OA producing strain (EcΔyhhS / 3HA_pMW) in which the YhhS function was deficient prepared in Reference Example 4, a 3HA production test was conducted in the same manner as in Comparative Example 1. The results are shown in Table 1.

[0172] Comparing the results of Comparative Example 1 and Reference Example 5, the 3HA yield of the 3HA and / or 3OA producing strain (Reference Example 5) in which the YhhS function was defective was reduced compared to the control strain (Comparative Example 1) in which the YhhS function was not defective. These results and the knowledge that YhhS has the function of excreting organophosphate compounds so far indicate that YhhS has the function of excreting 3HA, thereby contributing to the improvement of the productivity of 3HA.

[0173] Reference Example 6

[0174] Preparation of 3HA and / or 3OA producing strain with restored YhhS function

[0175] For EcΔyhhS in which the function of YhhS was deleted, the plasmids pBBRc::ATCTOR and pMW::EcYHHS prepared in Reference Examples 1 and 2 were introduced in the same manner as in Reference Example 4 to prepare a 3HA and / or 3OA production strain (EcΔyhhS / 3HA_EcYHHS) in which the function of YhhS was restored.

[0176] Reference Example 7

[0177] 3HA production test of 3HA and / or 3OA producing strains with restored YhhS function

[0178] To further confirm that YhhS has a 3HA excretion function, a 3HA production test was conducted in the same manner as in Comparative Example 1 using the 3HA and / or 3OA producing strain (EcΔyhhS / 3HA_EcYHHS) in which the function of YhhS was restored, prepared in Reference Example 6. The results are shown in Table 1.

[0179] Comparison of the results of Reference Example 5 and Reference Example 7 further demonstrates that: compared with the 3HA and / or 3OA production strain in which the function of YhhS is defective (Reference Example 5), the 3HA yield of the 3HA and / or 3OA production strain in which the function of YhhS is restored (Reference Example 7) is increased, and YhhS has the function of excreting 3HA, which helps to improve the productivity of 3HA.

[0180] Example 1

[0181] Preparation of 3HA and / or 3OA producing strain with enhanced expression of YhhS

[0182] For E. coli str.K-12 substr.BW25113, the plasmids pBBRc::ATCTOR and pMW::EcYHHS prepared in Reference Examples 1 and 2 were introduced in the same manner as in Reference Example 4 to prepare a 3HA and / or 3OA producing strain (EcWT / 3HA_EcYHHS) with enhanced expression of YhhS.

[0183] Example 2

[0184] 3HA production test of 3HA and / or 3OA producing strains with enhanced YhhS expression

[0185] In order to confirm the effect of improving 3HA productivity due to increased expression of YhhS, a 3HA and / or 3OA production strain (EcWT / 3HA_EcYHHS) with increased expression of YhhS prepared in Example 1 was used to perform a 3HA production test in the same manner as in Comparative Example 1. The results are shown in Table 1.

[0186] Comparing the results of Comparative Example 1 and Example 2, the 3HA yield of the 3HA and / or 3OA production strain (Example 2) with increased expression of YhhS was increased compared to the control strain (Comparative Example 1). Therefore, it is shown that by increasing the expression amount of YhhS, the 3HA excretion function is strengthened, thereby improving the productivity of 3HA.

[0187] [Table 1]

[0188] strains 3HA yield (%) Comparative Example 1 EcWT / 3HA_pMW 1.65 Reference Example 5 EcΔyhhS / 3HA_pMW 1.19 Reference Example 7 EcΔyhhS / 3HA_EcYHHS 1.47 Example 2 EcWT / 3HA_EcYHHS 1.86

[0189] Comparative Example 2

[0190] 3OA production test of control strain

[0191] A platinum ring of the control strain (EcWT / 3HA_pMW) was inoculated into 5 mL of medium I (φ18 mm glass test tube, aluminum plug) adjusted to pH 7 and incubated at 30°C for 120 min. -1 The culture was shaken for 24 hours. 0.25 mL of the culture solution was added to 5 mL of medium III (10 g / L glucose, 10 g / L sodium succinate, 1 g / L ammonium sulfate, 50 mM potassium phosphate, 0.025 g / L magnesium sulfate, 0.0625 mg / L iron sulfate, 2.7 mg / L manganese sulfate, 0.33 mg / L calcium chloride, 1.25 g / L sodium chloride, 2.5 g / L Bacto tryptone, 1.25 g / L Bacto yeast extract, 15 μg / mL chloramphenicol, 100 μg / mL ampicillin) (φ18 mm glass test tube, aluminum plug) adjusted to pH 6.5 and shaken at 30°C.

[0192] The supernatant after centrifugal separation of the bacterial cells from the obtained culture solution was analyzed in the same manner as in Comparative Example 1, thereby quantifying the concentrations of 3OA and other products accumulated in the culture supernatant, and sugars remaining in the culture medium that were not utilized. Furthermore, the yield of 3OA calculated based on the results using the following formula (3) is shown in Table 2.

[0193] 3OA yield (%) = 3OA production (mol) / sugar consumption (mol) × 100···Formula (3).

[0194] Example 3

[0195] 3OA production test of 3HA and / or 3OA producing strains with enhanced YhhS expression

[0196] In order to confirm the effect of improving 3OA productivity caused by the increased expression of YhhS, a 3OA production test was performed in the same manner as in Comparative Example 2 using the 3HA and / or 3OA production strain (EcWT / 3HA_EcYHHS) with increased expression of YhhS prepared in Example 1. The results are shown in Table 2.

[0197] Comparing the results of Comparative Example 2 and Example 3, the 3OA yield of the 3HA and / or 3OA production strain (Example 3) with increased expression of YhhS was increased compared to the control strain (Comparative Example 2). Therefore, it was shown that by increasing the expression of YhhS, the 3OA excretion function was enhanced, thereby increasing the productivity of 3OA.

[0198] [Table 2]

[0199] strains 3OA yield (%) Comparative Example 2 EcWT / 3HA_pMW 2.82 Example 3 EcWT / 3HA_EcYHHS 3.11

[0200] Reference Example 8

[0201] Preparation of plasmids for expressing various transport proteins

[0202] In order to amplify the upstream region of the promoter containing the yhhS gene of Escherichia coli and the downstream region containing the terminator, the genomic DNA of Escherichia coli str.K-12substr.MG1655 strain was used as a template to amplify the upstream 0.5kb and downstream 0.5kb of the yhhS gene. The primers used the nucleic acids of sequence numbers 34 and 35, 36 and 37, respectively. The PCR fragment was connected with the fragment obtained by cutting the expression vector pMW119 (manufactured by Nippon Gene Co., Ltd.) that can replicate autonomously in Escherichia coli using SacI and KpnI using In-Fusion HD Cloning Kit, and introduced into the Escherichia coli DH5α strain. The plasmid was extracted from the obtained recombinant strain, and the plasmid whose base sequence was confirmed according to the conventional method was set to pMW::Pro-Ter.

[0203] Reference Example 9

[0204] Preparation of plasmids expressing YhhS homologs

[0205] In order to express the YhhS homolog, the yhhS homologous sequence of the Salmonella enterica ATCC9150 strain was synthesized, and the full length of the gene was amplified using the sequence as a template and the nucleic acids of sequence numbers 38 and 39 as primers. The PCR fragment was connected to the fragment obtained by cutting pMW::Pro-Ter with SacI and KpnI using the In-Fusion HD Cloning Kit and introduced into the Escherichia coli DH5α strain. The plasmid was extracted from the obtained recombinant strain, and the plasmid whose base sequence was confirmed according to the conventional method was set to pMW::SeYHHS.

[0206] Similarly, gene synthesis was performed on the yhhS homologous sequence of Klebsiella pneumoniae MGH78578 strain, and the full length of the gene was amplified using the sequence as a template and the nucleic acids of sequence numbers 40 and 41 as primers. The PCR fragment was inserted into pMW::Pro-Ter by the same method as that used to make pMW::SeYHHS, and the resulting plasmid was set to pMW::KpYHHS.

[0207] Similarly, gene synthesis was performed for the yhhS homologous sequence of the Pectobacterium carotovorum PC1 strain, and the full length of the gene was amplified using the sequence as a template and the nucleic acids of sequence numbers 42 and 43 as primers. The PCR fragment was inserted into pMW::Pro-Ter by the same method as when making pMW::SeYHHS, and the resulting plasmid was set to pMW::PcYHHS.

[0208] Similarly, the full length of the gene was amplified using genomic DNA of Serratia grimesii strain NBRC13537 as a template and nucleic acids of SEQ ID NOs: 44 and 45 as primers. The PCR fragment was inserted into pMW::Pro-Ter in the same manner as in the preparation of pMW::SeYHHS, and the resulting plasmid was designated pMW::SgYHHS.

[0209] Example 4

[0210] Preparation of 3HA and / or 3OA producing strain with enhanced expression of YhhS homolog

[0211] For E. coli str.K-12 substr.BW25113, the plasmid pBBRc::ATCTOR prepared in Reference Example 1 was introduced by the same method as in Reference Example 4. For the obtained strain, the plasmid pMW::SeYHHS, pMW::KpYHHS, pMW::PcYHHS, or pMW::SgYHHS prepared in Reference Example 9 was introduced to prepare 3HA and / or 3OA production strains (EcWT / 3HA_SeYHHS, EcWT / 3HA_KpYHHS, EcWT / 3HA_PcYHHS, EcWT / 3HA_SgYHHS) in which the expression of YhhS homologs was increased.

[0212] Example 5

[0213] 3HA production test of 3HA and / or 3OA producing strains with increased expression of YhhS homologs

[0214] In order to confirm the effect of improving 3HA productivity caused by the increased expression of YhhS homologs, the 3HA and / or 3OA production strains (EcWT / 3HA_SeYHHS, EcWT / 3HA_KpYHHS, EcWT / 3HA_PcYHHS, EcWT / 3HA_SgYHHS) with increased expression of YhhS homologs prepared in Example 4 were used to perform a 3HA production test in the same manner as in Comparative Example 1. The results are shown in Table 3.

[0215] Comparing the results of Comparative Example 1 and Example 5, the 3HA yield of the 3HA and / or 3OA production strain (Example 5) in which the expression of the YhhS homolog was increased was improved compared with the control strain (Comparative Example 1). Therefore, it was shown that by increasing the expression amount of the YhhS homolog, the 3HA excretion function was strengthened, thereby improving the productivity of 3HA.

[0216] [Table 3]

[0217] strains 3HA yield (%) Comparative Example 1 EcWT / 3HA_pMW 1.65 Example 5 EcWT / 3HA_SeYHHS 2.09 Example 5 EcWT / 3HA_KpYHHS 1.87 Example 5 EcWT / 3HA_PcYHHS 1.93 Example 5 EcWT / 3HA_SgYHHS 1.92

[0218] Example 6

[0219] 3OA production test of 3HA and / or 3OA producing strains with enhanced expression of YhhS homologs

[0220] In order to confirm the effect of improving 3OA productivity caused by the increased expression of YhhS homologs, the 3HA and / or 3OA production strains (EcWT / 3HA_SeYHHS, EcWT / 3HA_KpYHHS, EcWT / 3HA_PcYHHS, EcWT / 3HA_SgYHHS) with increased expression of YhhS homologs prepared in Example 4 were used to perform a 3OA production test in the same manner as in Comparative Example 2. The results are shown in Table 4.

[0221] Comparing the results of Comparative Example 2 and Example 6, the 3OA production rate of the 3HA and / or 3OA production strain (Example 6) with increased expression of the YhhS homolog was increased compared to the control strain (Comparative Example 2). Therefore, it is shown that by increasing the expression amount of the YhhS homolog, the 3OA excretion function is strengthened, thereby increasing the productivity of 3OA.

[0222] [Table 4]

[0223] strains 3OA yield (%) Comparative Example 2 EcWT / 3HA_pMW 2.82 Example 6 EcWT / 3HA_SeYHHS 3.11 Example 6 EcWT / 3HA_KpYHHS 3.29 Example 6 EcWT / 3HA_PcYHHS 4.70 Example 6 EcWT / 3HA_SgYHHS 3.30

[0224] Reference Example 10

[0225] Preparation of plasmid expressing organophosphate compound excretion vector

[0226] In order to express the organophosphate compound excretion vector MdtD, the full length of the gene was amplified using genomic DNA of Escherichia coli str.K-12 substr.MG1655 as a template and nucleic acids of sequence numbers 52 and 53 as primers. The PCR fragment was inserted into pMW::Pro-Ter by the same method as that used to prepare pMW::SeYHHS, and the resulting plasmid was designated pMW::EcMDTD.

[0227] Similarly, in order to express RhtB, the full length of the gene was amplified using genomic DNA of Escherichia coli str. K-12 substr. MG1655 as a template and nucleic acids of sequence numbers 54 and 55 as primers. The PCR fragment was inserted into pMW::Pro-Ter by the same method as in the preparation of pMW::SeYHHS, and the resulting plasmid was designated pMW::EcRHTB.

[0228] Similarly, in order to express MFS40, the full length of the gene was amplified using the gene of the synthetic Aspergillus oryzae RIB40 strain as a template and the nucleic acids of SEQ ID NOs: 56 and 57 as primers. The PCR fragment was inserted into pMW::Pro-Ter by the same method as that for preparing pMW::SeYHHS, and the resulting plasmid was designated pMW::AoMFS40.

[0229] Example 7

[0230] Preparation of 3HA and / or 3OA producing strain with enhanced expression of organophosphate compound excretion vector

[0231] For E. coli str.K-12 substr.BW25113, the plasmid pBBRc::ATCTOR prepared in Reference Example 1 was introduced by the same method as in Reference Example 4. For the obtained strain, the plasmid pMW::EcMDTD, pMW::EcRHTB, or pMW::AoMFS40 prepared in Reference Example 10 was introduced to prepare 3HA and / or 3OA production strains (EcWT / 3HA_EcMDTD, EcWT / 3HA_EcRHTB, EcWT / 3HA_AoMFS40) with increased expression of the organophosphate compound excretion vector.

[0232] Example 8

[0233] 3HA production test of 3HA and / or 3OA producing strains with enhanced expression of organophosphate excretion vector

[0234] In order to confirm the effect of improving 3HA productivity due to the increased expression of the organophosphate compound excretion vector, the 3HA and / or 3OA production strains (EcWT / 3HA_EcMDTD, EcWT / 3HA_EcRHTB, EcWT / 3HA_AoMFS40) prepared in Example 7 with increased expression of the organophosphate compound excretion vector were used to perform a 3HA production test in the same manner as in Comparative Example 1. The results are shown in Table 5.

[0235] Comparing the results of Comparative Example 1 and Example 8, the 3HA and / or 3OA producing strain (Example 8) in which the expression of the organophosphate compound excretion vector was increased had an increased 3HA yield compared to the control strain (Comparative Example 1). Therefore, it was shown that by increasing the expression amount of the organophosphate compound excretion vector, the 3HA excretion function was enhanced, thereby increasing the productivity of 3HA.

[0236] [Table 5]

[0237] strains 3HA yield (%) Comparative Example 1 EcWT / 3HA_pMW 1.65 Example 8 EcWT / 3HA_EcMDTD 2.01 Example 8 EcWT / 3HA_EcRHTB 1.86 Example 8 EcWT / 3HA_AoMFS40 1.79

[0238] Reference Example 11

[0239] Preparation of 3HA and / or 3OA producing strain with increased expression of protein belonging to MFS and not having organophosphate compound excretion function

[0240] YhhS, MdtD, and MFS40 are all proteins belonging to MFS. Here, in order to verify whether proteins belonging to MFS and not having an organophosphate compound excretion function have a 3HA excretion function, a 3HA and / or 3OA producing strain with enhanced expression of EmrD was prepared.

[0241] EmrD is a protein belonging to MFS called multidrug resistance protein D. As a specific example, EmrD (NCBI Protein ID: NP_418129, sequence number 58) from Escherichia coli str. K-12 substr. MG1655 strain can be cited, and as a gene encoding EmrD, emrD (NCBI Gene ID: 948180, sequence number 59) from Escherichia coli str. K-12 substr. MG1655 strain can be cited. It is recorded in Japanese Patent Publication No. 2017-528126 that EmrD does not have the function of excreting O-phosphoserine as an organic phosphate compound.

[0242] In order to express EmrD, the full length of the gene was amplified using genomic DNA of Escherichia coli str. K-12 substr. MG1655 as a template and nucleic acids of SEQ ID NOs: 60 and 61 as primers. The PCR fragment was inserted into pMW::Pro-Ter by the same method as that for preparing pMW::SeYHHS, and the resulting plasmid was designated pMW::EcEMRD.

[0243] Reference Example 12

[0244] Preparation of 3HA and / or 3OA producing strain with increased expression of protein belonging to MFS and not having organophosphate compound excretion function

[0245] For E. coli str.K-12 substr.BW25113, the plasmid pBBRc::ATCTOR prepared in Reference Example 1 was introduced by the same method as in Reference Example 4. The plasmid pMW::EcEMRD prepared in Reference Example 11 was introduced into the obtained strain to prepare a 3HA and / or 3OA production strain (EcWT / 3HA_pMW::EcEMRD) in which the expression of a protein belonging to MFS and having no organophosphate compound excretion function was increased.

[0246] Reference Example 13

[0247] 3HA production test of 3HA and / or 3OA producing strains with increased expression of proteins belonging to MFS and not having organophosphate compound excretion function

[0248] Using the 3HA and / or 3OA producing strain (EcWT / 3HA_pMW::EcEMRD) prepared in Reference Example 12 and having increased expression of a protein belonging to MFS and not having an organophosphate compound excretion function, a 3HA production test was conducted in the same manner as in Comparative Example 1. The results are shown in Table 6.

[0249] Comparing the results of Comparative Example 1 and Reference Example 13, the 3HA yield of the 3HA and / or 3OA producing strain (Reference Example 13) in which the expression of the organophosphate compound excretion vector was increased was lower than that of the control strain (Comparative Example 1). Therefore, it was shown that the increase in the expression amount of the protein that does not have the organophosphate compound excretion function does not enhance the 3HA excretion function, and the productivity of 3HA is not improved.

[0250] [Table 6]

[0251] strains 3HA yield (%) Comparative Example 1 EcWT / 3HA_pMW 1.65 Reference Example 13 EcWT / 3HA_EcEMRD 1.45

Claims

1. A genetically modified microorganism having an ability to produce 3-hydroxyadipic acid and / or 3-oxoadipic acid, wherein the activity of an enzyme catalyzing the reaction from succinyl-CoA and acetyl-CoA to 3-oxoadipoyl-CoA and CoA is enhanced, and the expression level of an organophosphate compound excretion vector is increased.

2. The genetically modified microorganism according to claim 1, wherein The organophosphate compound excretion carrier is a phosphoserine excretion carrier and / or a glyphosate excretion carrier.

3. The genetically modified microorganism according to claim 1 or 2, wherein The organophosphate compound excretion carrier is YhhS, MdtD, RhtB, MFS40 or homologs thereof.

4. The genetically modified microorganism according to any one of claims 1 to 3, wherein the expression level of the organophosphate compound excretion vector is increased by introducing a gene encoding any one of the following polypeptides (A) to (C), (A) a polypeptide consisting of the amino acid sequence of SEQ ID NOs: 1, 3, 28 to 30, 46, 48 or 50; (B) a polypeptide having a sequence identity of 60% or more to the amino acid sequence of SEQ ID NOs: 1, 3, 28 to 30, 46, 48 or 50, and having a function of increasing the productivity of 3-hydroxyadipic acid and / or 3-oxoadipic acid; (C) A polypeptide consisting of an amino acid sequence in which one or more amino acids are substituted, deleted, inserted and / or added in the amino acid sequence of SEQ ID NOs: 1, 3, 28 to 30, 46, 48 or 50, and having a function of increasing the productivity of 3-hydroxyadipic acid and / or 3-oxoadipic acid.

5. The genetically modified microorganism according to any one of claims 1 to 4, further comprising an enhanced activity of an enzyme that catalyzes a reaction of reducing 3-oxoadipyl-CoA to produce 3-hydroxyadipyl-CoA and / or a reaction of producing 3-hydroxyadipic acid from 3-hydroxyadipyl-CoA.

6. The genetically modified microorganism according to any one of claims 1 to 5, wherein the activity of an enzyme that catalyzes the reaction of producing 3-oxoadipate from 3-oxoadipyl-CoA is further enhanced.

7. The genetically modified microorganism according to any one of claims 1 to 6, wherein The microorganism is a microorganism belonging to the genus Escherichia coli or Serratia.

8. A method for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid, comprising the step of culturing the genetically modified microorganism according to any one of claims 1 to 7.

9. A method for producing a genetically modified microorganism, comprising: A step of enhancing the activity of an enzyme that catalyzes the reaction from succinyl-CoA and acetyl-CoA to 3-oxoadipyl-CoA and CoA in a microorganism having the ability to produce 3-hydroxyadipate and / or 3-oxoadipate by genetic modification; and a step of increasing the expression amount of YhhS or its homolog in the microorganism.

10. A method for producing 3-hydroxyadipic acid and / or 3-oxoadipic acid, comprising the step of culturing a microorganism capable of producing 3-hydroxyadipic acid and / or 3-oxoadipic acid in which the expression level of an organophosphate compound excretion vector is increased.

11. A method for producing adipic acid, comprising: A step A of producing 3-hydroxyadipic acid and / or 3-oxoadipic acid by the method according to claim 8 or 10; and a step B (i.e., a hydrogenation step) of reacting 3-hydroxyadipic acid and / or 3-oxoadipic acid with hydrogen in the presence of a hydrogenation catalyst.

12. A method for producing a polyamide, comprising: A step of producing adipic acid by the method according to claim 11; and a step C of polycondensing adipic acid and diamine.

13. The method for producing polyamide according to claim 11, wherein: The diamine is a diamine containing 1,4-butanediamine, 1,5-pentanediamine or hexamethylenediamine.

Citation Information

Patent Citations

  • 6—Simultaneous production of aminocapronitrile and hexamethylenediamine

    JP2000508305A

  • O-phosphoserine-producing microorganisms and methods for producing O-phosphoserine or L-cysteine ​​using the same

    JP2017528126A

  • Microorganisms for the production of adipic acid and other compounds

    WO2009151728A2

  • Method for producing 3-hydroxyadipic acid

    WO2017209102A1

  • Gene-modified microorganism for producing 3-hydroxyadipic acid, α-hydromuconic acid and / or adipic acid, and production method for said chemical products

    WO2019107516A1